The influence of ACYP2 polymorphisms on gastrointestinal cancer susceptibility in the Chinese Han population

Abstract

Background Gastrointestinal cancer (GI cancer) is a type of cancer that has a high death rate. It has been reported that ACYP2 gene was associated with the development of gastric cancer and colorectal cancer, but it is not clear that the relationship between ACYP2 gene and GI cancer in Chinese Han population. This study aimed to investigate the association between polymorphisms of ACYP2 and GI cancer in the Chinese Han population. Methods We used Agena MassARRAY to determine the genotypes of 1,160 GI cancer patients and 495 healthy controls. The correlation between ACYP2 variants and GI cancer risk was examined by logistic regression analysis. Results We identified that rs6713088 (OR = 1.17, 95% CI: 1.00–1.36, p = 0.047), rs843711 (OR = 1.17, 95 CI: 1.01–1.36, p = 0.035), and rs11896604 (OR = 1.20, 95% CI: 1.00–1.45, p = 0.048) were correlated with an increased risk of GI cancer under allele model. Rs11125529 under the recessive model (OR = 2.05, 95% CI: 1.00–4.23, p = 0.038), rs843711 in recessive model (OR = 1.37, 95% CI: 1.04–1.82, p = 0.026), and rs11896604 under log‐additive model (OR = 1.23, 95% CI: 1.01–1.51, p = 0.042) were associated with an increased risk of GI cancer. Conclusion Our study suggested that polymorphisms of ACYP2 gene might be associated with susceptibility to GI cancer.

Prognostic significance of X-linked inhibitor of apoptosis protein in patients with gastrointestinal tract cancers

“…[ 3 ] The early symptoms of GIT cancers are not obvious and they are easily misdiagnosed with other diseases. [ 4 , 5 ] In recent years, many anticancer strategies and the mechanisms have been explored. [ 6 – 9 ] Despite the great improvements in the diagnosis and treatment of GIT cancers, the 5-year survival rate is still low, especially colorectal cancer, gastric cancer and esophageal cancer.…”

“…[ 6 – 9 ] Despite the great improvements in the diagnosis and treatment of GIT cancers, the 5-year survival rate is still low, especially colorectal cancer, gastric cancer and esophageal cancer. [ 5 ] Therefore, it is worthwhile to explore new prognostic biomarkers and potential therapeutic targets for better management of GIT cancers.…”